Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial

G. J. Mertz, C. C. Jones, J. Mills, K. H. Fife, S. M. Lemon, J. T. Stapleton, E. L. Hill and L. G. Davis
Department of Medicine, University of New Mexico School of Medicine, Albuquerque 87131.

Normal adults with six or more episodes of genital herpes in the previous year were enrolled in a one-year, multicenter, double-blind trial comparing placebo with 400 mg of acyclovir administered orally twice daily. Patients with episodes during the study were offered 200 mg of acyclovir administered orally five times daily for five days; this allowed comparison of suppressive and episodic treatment. After one year, 227 (44%) of 519 patients receiving suppressive treatment and seven (2%) of 431 receiving placebo (episodic) treatment remained free of recurrences, and the mean numbers of recurrences per year were 1.8 and 11.4, respectively. Among 67 patients who had received suppressive therapy for one year, the mean duration of lesions in the first episode following the discontinuation of treatment was 9.3 days compared with 7.3 days among 45 patients who had received episodic therapy for one year. Treatment was well tolerated, and no changes were noted in the in vitro susceptibility to acyclovir of herpes simplex virus cultured during or after the one-year trial. Continuous or episodic oral acyclovir therapy for one year remained safe and effective.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Treatment of Herpes Simplex Infections: An Evidence-Based Review
Cernik et al.
Arch Intern Med 2008;168:1137-1144.
ABSTRACT | FULL TEXT  

Genital herpes and its management
Sen and Barton
BMJ 2007;334:1048-1052.
FULL TEXT  

Patient satisfaction with care for genital herpes: insights from a global survey
Patrick et al.
Sex. Transm. Infect. 2004;80:192-197.
ABSTRACT | FULL TEXT  

Genital Herpes
Kimberlin and Rouse
NEJM 2004;350:1970-1977.
FULL TEXT  

Long-term Acyclovir Use to Prevent Recurrent Ocular Herpes Simplex Virus Infection
Uchoa et al.
Arch Ophthalmol 2003;121:1702-1704.
ABSTRACT | FULL TEXT  

Imiquimod 5-Percent Cream Does Not Alter the Natural History of Recurrent Herpes Genitalis: a Phase II, Randomized, Double-Blind, Placebo-Controlled Study
Schacker et al.
Antimicrob. Agents Chemother. 2002;46:3243-3248.
ABSTRACT | FULL TEXT  

The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin
Halberstadt et al.
Br. J. Ophthalmol. 2002;86:646-652.
ABSTRACT | FULL TEXT  

Can We Prevent Recurrences of Herpes Infections without Antiviral Drugs? The Weisenfeld Lecture
Kaufman
IOVS 2002;43:1325-1329.
FULL TEXT  

Once-Daily Valacyclovir Hydrochloride for Suppression of Recurrent Genital Herpes
BAKER et al.
Obstet Gynecol 1999;94:103-106.
ABSTRACT | FULL TEXT  

Oral Acyclovir After Penetrating Keratoplasty for Herpes Simplex Keratitis
Tambasco et al.
Arch Ophthalmol 1999;117:445-449.
ABSTRACT | FULL TEXT  

Oral Famciclovir for the Suppression of Recurrent Genital Herpes: A Randomized Controlled Trial
Diaz-Mitoma et al.
JAMA 1998;280:887-892.
ABSTRACT | FULL TEXT  

Acyclovir for the Prevention of Recurrent Herpes Simplex Virus Eye Disease
Wilhelmus et al.
NEJM 1998;339:300-306.
ABSTRACT | FULL TEXT  

ACYCLOVIR SUPPRESSES RECURRENCE OF GENITAL HERPES
JWatch General 1988;1988:3-3.
FULL TEXT